- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04137068
Sedentary Behavior, Cardiovascular Function, and Sleep (PACE)
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
PRIMARY OBJECTIVES:
1. To test the hypothesis that two weeks of sedentary behavior will progressively impair vascular endothelial function.
2: To test the hypothesis that increasing sedentary behavior will decrease total sleep duration and sleep efficiency.
3: To test the hypothesis that two-weeks of sedentary behavior will progressively increase 24-h blood pressure and reduce nocturnal blood pressure dipping.
OUTLINE:
After a baseline period, participants will become more inactive and also come in for 4-h uninterrupted sitting visits. Cardiovascular, activity, and sleep measures will be taken throughout.
Type d'étude
Inscription (Anticipé)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Oregon
-
Portland, Oregon, États-Unis, 97239
- Recrutement
- Oregon Institute of Occupational Health Sciences
-
Contact:
- Saurabh Thosar, Dr.
- Numéro de téléphone: 503-494-2064
- E-mail: thosar@ohsu.edu
-
Chercheur principal:
- Saurabh Thosar, Dr.
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Ages 20-80y
- Lean and overweight (BMI 18.5-40 kg/m2)
- No acute, chronic, or debilitating medical conditions
- No prescription/non-prescription medications or drugs of abuse
- Limited weight training or intense exercise (swimming, CrossFit)
- Non-smoker
- Average level of daily physical activity (8,000-12,499 steps/day)
- Persons who fit all the above criteria and are suitable based on a medical history and health habits questionnaire, sleep profiling questionnaire, and electrocardiogram and clinical biochemical screening tests of blood and urine may be eligible to participate.
Exclusion Criteria:
- Persons with any acute, chronic, or debilitating medical condition except pre-hypertension and/or mild to moderate sleep apnea will be excluded.
- Persons with any symptoms of acute or active illness (e.g. fever, leukocytosis) will be excluded.
- Persons with a history of severe psychiatric illness or psychiatric disorders will be excluded.
- Persons with a history of regular night/or rotating shift work, or who have traveled more than three time zones during the one month prior to the study will be excluded.
- Pregnant persons, decisionally impaired adults, and prisoners will be excluded.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Autre
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Autre: Sedentary to Active
Participants will visit the research laboratory for baseline measurements at visit 1 after wearing a pedometer for one week and maintaining their typical level of physical activity.
After the baseline visit, participants will reduce their step count by more than half for two weeks.
Participants will visit the laboratory once every week during the 2 week interventional period for a total of 3 visits.
|
Participants reduce their activity level to <5,000 steps/day and <50 % of baseline steps.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Endothelial Function
Délai: 3 weeks
|
Investigators will measure endothelial function as flow-mediated dilation at baseline, and each hour of the 3-hour sitting trials.
|
3 weeks
|
|
Oxidative stress
Délai: 3 weeks
|
Oxidative stress will be measured using malondialdehyde adducts (MDA) from Ethylenediaminetetraacetic acid (EDTA) plasma.
|
3 weeks
|
|
Endothelin-1
Délai: 3 weeks
|
Endothelin 1 (ET-1) will be measured from Ethylenediaminetetraacetic acid (EDTA) plasma.
|
3 weeks
|
|
Heart rate
Délai: 3 weeks
|
During the weekly trials, heart rate will be measured as beats per minute while participants are in a seated position during the prolonged sitting period.
|
3 weeks
|
|
Blood pressure
Délai: 3 weeks
|
During the weekly trials, blood pressure will be measured as systolic over diastolic in a seated position in the dominant arm
|
3 weeks
|
|
24-hour BP measurement
Délai: 3 weeks
|
Investigators will measure 24-hour ambulatory blood pressure monitoring (AMBP, Spacelabs, Inc) at baseline and for 24-h before each in-lab visit.
|
3 weeks
|
|
Sleep duration
Délai: 3 weeks
|
Sleep duration will be scored from the ActiGraph and correlated with the sleep and activity diary.
|
3 weeks
|
|
Sleep efficiency
Délai: 3 weeks
|
Sleep efficiency will be scored from the ActiGraph and correlated with the sleep and activity diary.
|
3 weeks
|
|
Activity
Délai: 3 weeks
|
Activity will be scored from the ActiGraph and correlated with the sleep and activity diary.
|
3 weeks
|
|
Activity Perception
Délai: 3 weeks
|
Activity perception will be measured before each prolonged sitting trial using an Activity Perception questionnaire (Perception of Current Activity Questionnaire).
The questionnaire has 7 questions with answers ranging from 1 to 5. The range of scores is from 7 to 35, with 7 suggesting a strong negative perception of current activity, and 35 suggesting a strong positive perception of current activity.
|
3 weeks
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Saurabh Thosar, Dr., Oregon Institute of Occupational Health Sciences
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Autres numéros d'identification d'étude
- STUDY00020458
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .